Epidemiology and management of coexisting heart failure and atrial fibrillation in anoutpatient setting

Polskie Archiwum Medycyny Wewnetrznej

Volumn 121, Issue 11, 2011, Pages 392-399

  Rewiuk, Krzysztof ^a   Wizner, Barbara ^a   Fedyk Łukasik, Małgorzata ^a   Zdrojewski, Tomasz ^b   Opolski, Grzegorz ^c   Dubiel, Jacek ^a   Ga̧sowski, Jerzy ^a   Grodzicki, Tomasz ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Atrial fibrillation; Epidemiology; Heart failure; Treatment

Indexed keywords

ACENOCOUMAROL; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE;

AGED; ANEMIA; ARTICLE; CHRONIC LUNG DISEASE; CLINICAL ASSESSMENT; COMORBIDITY; CORONARY ARTERY DISEASE; DEMOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; POLAND; PREVALENCE; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; STROKE; THYROID DISEASE; VALVULAR HEART DISEASE;

EID: 83055168978     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Kannel WB, Abbot RD, Savage DD, McNamara PM. Epidemiological features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982; 306: 1018-1022. (Pubitemid 12155370)
2. American Heart Association: Heart and Stroke Statistical Update. United States, Dallas, TX: American Heart Association; 2002.
3. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology and rationale for therapy. Am J Cardiol. 2003; 91 (6A): 2D-8D. (Pubitemid 36369329)
4. Savelieva I, John Camm A. Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace. 2004; 5: S5-S19. (Pubitemid 39193160)
5. Heist EK, Ruskin JN. Atrial fibrillation and congestive heart failure: risk factors, mechanisms and treatment. Prog Cardiovasc Dis. 2006; 48: 256-269. (Pubitemid 43326301)
6. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure. Treatment considerations for a dual epidemic. Circulation. 2009; 119: 2516-2525.
7. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 1992; 327: 685-691.
8. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). CONSENSUS Trial Study Group. NEngl J Med. 1987; 316: 1429-1435.
9. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998; 98: 946-952. (Pubitemid 28446646)
10. Dries DL, Exner DV, Gersh BJ. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998; 32: 695-703. (Pubitemid 28435256)
11. Carson PE, Johnson GR, Dunkman WB, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. Circulation. 1993; 87 (6 Suppl): VI102-VI110. (Pubitemid 23164229)
12. Crijns HJGM, Tjeerdsma G, de Kam PJ, etal. Prognostic value of the presence of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J. 2000; 21: 1238-1245. (Pubitemid 30487771)
13. Badano LP, Di Lenarda A, Bellotti P, et al. Patients with chronic heart failure encountered in daily clinical practice are different from the "typical" patient enrolled in therapeutic trials. Ital Heart J. 2003; 4: 84-91. (Pubitemid 36701807)
14. Wizner B, Dubiel J, Zdrojewski T, et al. Polish study for assessment of diagnosis, treatment and costs of heart failure in Poland in random sample of out-patient clinics and hospitals, at different levels of care. Methodological aspects of the study had been realized as a apart of the National Project for the Prevention and Treatment of Cardiovascular Diseases (PolKARD 2003-2005). Folia Cardiol. 2006; 1: 2-9.
15. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Eur Heart J. 2003; 24: 442-463. (Pubitemid 36286187)
16. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006; 27: 2725-2736. (Pubitemid 44729876)
17. Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational Research Programme: the heart failure pilot survey. Eur J Heart Fail. 2010; 12: 1076-1084.
18. Yancy CW, Fonarow GC, Albert NM, et al. Adherence to guideline- recommended adjunctive heart failure therapies among outpatient cardiology practices (findings from IMPROVE HF). Am J Cardiol. 2010; 105: 255-260.
19. Muntwyler J, Cohen-Solal A, Freemantle N, et al. Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail. 2004; 6: 663-668. (Pubitemid 39070522)
20. Pulignano G, Del Sindaco D, Tavazzi L, et al.; IN-CHF Investigators. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from alarge nationwide cardiology database (IN-CHF Registry). Am Heart J. 2002; 143: 45-55. (Pubitemid 34056374)
21. Tsutsui H, Tsuchihaschi-Makaya M, Kinugawa S, et al. Characteristics and outcomes of patient with heart failure in general practices and hospitals - Japanese cardiac registry of heart failure in general practice (JCARE-GENERAL). Circ J. 2007; 71: 449-454. (Pubitemid 46513447)
22. Lenzen MJ, Rosengren A, Scholte OP, et al. Management of patients with heart failure in clinical practice: differences between men and women. Heart. 2008; 94: e10.
23. Nieminen MS, Harjola VP, Hochadel M, et al. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. Eur J Heart Fail. 2008; 10: 140-148. (Pubitemid 351221390)
24. De Ferrari GM, Klersy C, Ferrero P, et al. Atrial fibrillation in heart failure patients: prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur J Heart Fail. 2007; 9: 502-509. (Pubitemid 46561482)
25. Hamaguchi S, Yokoshiki H, Kinugawa S, et al. Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan - a report from the Japanese Cardiac Registry of heart failure in cardiology (JCARE-CARD). Circ J. 2009; 73: 2084-2090.
26. Køber L, Swedberg K, McMurray JJ, et al. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. Eur J Heart Fail. 2006; 8: 591-598. (Pubitemid 44604352)
27. Jons C, Jacobsen UG, Joergensen RM, et al. The incidence and prognostic significance of new-onset atrial fibrillation in patients with acute myocardial infarction and left ventricular systolic dysfunction: a CARISMA substudy. Heart Rhythm. 2011; 8: 342-348.
28. Piccini JP, Hernandez AF, Zhao X, et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol. 2009; 54: 1280-1289.
29. Kaldara-Papatheodorou EE, Terrovitis JV, Nanas JN. Anemia in heart failure: should we supplement iron in patients with chronic failure? Pol Arch Med Wewn. 2010; 120: 354-360.
30. Ceia F, Fonseca C, Mota T, et al. Aetiology, comorbitidy and drug therapy of chronic heart failure in thereal world: the EPICA substudy. Eur J Heart Fail. 2004; 6: 801-806. (Pubitemid 39470238)
31. Baldasseroni S, Orso F, Fabbri G, et al. Age-dependent prognostic significance of atrial fibrillation on outpatients with chronic heart failure: data from the Italian Network on Congestive Heart Failure Registry. Cardiology. 2010; 116: 79-88.
32. Undas A, Cieśla-Dul M, Żółciński M, et al. Switching from acenocoumarol to warfarin in patients with unstable anticoagulation and its effect on anticoagulation control. Pol Arch Med Wewn. 2009; 119: 360-365.
33. Karthikeyan G, Eikelboom JW, Hirsh J. Dabigatran: ready for prime time? Pol Arch Med Wewn. 2010; 120: 137-142.
34. McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001; 161: 2458-2463. (Pubitemid 33043119)
35. Rewiuk K, Bednarz S, Faryan P, et al. [Prevalence and quality of antithrombotic treatment in patients with atrial fibrillation]. Folia Cardiol. 2003; 10: 633-640. Polish.
36. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003; 24: 464-474. (Pubitemid 36286188)
37. Sturm HB, Haaijer-Ruskamp FM, Veeger NJ, et al. The relevance of comorbidities for heart failure treatment in primary care: a European survey. Eur Heart J. 2006; 8: 31-37. (Pubitemid 43012098)
38. Yancy CW, Fonarow GC, Albert NM, et al. Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology setting: findings from IMPROVE HF. Am Heart J. 2009; 157: 754-762.e2.
39. Bongers FJ, Schellevis FG, Bakx C, et al. Treatment of heart failure in Dutch general practice. BMC Fam Pract. 2006; 7: 40.
40. Bellotti P, Badano LP, Acquarone N, et al.; OSCUR Investigators. Specialty-related differences in theepidemiology, clinical profile, management and outcome of patients hospitalized for heart failure; the OSCUR study. Oucome dello Scompenso Cardiaco in relazione all'Utilizzo delle Risore. Eur Heart J. 2001; 22: 596-604.
41. Stawicki S, Roik M, Jasik M, et al. Differences between cardiologists and internists in the management of heart failure. Medical guidelines compared with every-day practice. Kardiol Pol. 2004; 61: 431-439.
42. Vassilikos VP, Mantziari A, Goudis CA, et al. Differences of atrial fibrillation between cardiologists and non-cardiologists in Greece. Hellenic J Cardiol. 2010; 51: 113-121.
43. Pitt B. Angiotensin receptor blocker in patients with heart failure and a reduce left ventricular ejection fraction. Implications of the HEAAL Trial. Pol Arch Med Wewn. 2010; 120: 68-70.
44. Zareba W, Zareba KM. Which patients with chronic heart failure should be referred for CRT-D implantation? Practical implications of current clinical research. Pol Arch Med Wewn. 2010; 120: 95-102.
45. Opolski G, Kosior DA, Kurzelewski M, et al.; Polish RecordAF. Baseline characteristics of patients from Poland enrolled in the global registry of patients with recently diagnosed atrial fibrillation. Kardiol Pol. 2010; 68: 546-554.
46. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001; 22: 1527-1560. (Pubitemid 32801300)
47. Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: areport from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006; 27: 3018-3026. (Pubitemid 44963431)